A Pharma company approached MedQIA with developing and implementing novel imaging analysis criteria to show drug efficacy.
MedQIA developed an unique imaging biomarker for a longstanding client in support of a Phase 3 Metastatic Renal Cell Carcinoma study with an imaging endpoint.
The study required analysis of bone lesion metastases, and the sponsor turned to our experts for help in development and implementation of the novel imaging analysis criteria. Scientists, doctors, and software engineers joined together to bring their expertise to bear and successfully produce a unique Bone Scan Lesion Assessment analysis criteria.
Development of novel imaging analysis criteria
Developed a novel AI-guided lesion tracking on Bone Scans for PCWG2 with the aim of improving objectivity and reducing adjudication rates.
